MedTrace Logo

Study of Neoadjuvant Chemotherapy of Breast Cancer

NCT00830544 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2012-07-13

No results posted yet for this study

Summary

The purpose of this study is to evaluate the pathological CR rate in breast and lymph nodes of a novel neoadjuvant regimen for invasive breast carcinoma.

Conditions

Interventions

DRUG

Neoadjuvant chemotherapy

Docetaxel 75 mg/m2, day 1 Epirubicin 80 mg/m2, day 1 Cyclophosphamide 500 mg/m2, day 1 Navelbine 25 mg/M2 in 250 cc NS over 60 min on day 1 and day 8 Bevacizumab 5 mg/kg in 100 cc NS over 90 min day 1 and day 8 Capecitabine 825 mg/M2 p.o. bid from day 1-14. Trastuzumab

DRUG

Chemotherapy

Neoadjuvant chemotherapy

DRUG

Neoadjuvant chemotherapy

Experimental chemotherapy regimen

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • Auxilio Mutuo Cancer Center

    lead OTHER

Principal Investigators

  • Fernando Cabanillas, MD · Auxilio Mutuo Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2011-12-31
Completion
2012-12-31

Countries

  • Puerto Rico

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00830544 on ClinicalTrials.gov